ArticleDrug delivery2026
The development of DNA delivery system based on ionic liquid and carboxylic acid modified polyethyleneimine.
Article in Drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant DNA vaccines offer significant potential for disease prevention and therapy, but their clinical success is often limited by poor immunogenicity, low cellular uptake, instability, and inefficient delivery without proper carriers. To address these challenges, we developed a series of novel cationic delivery systems by modifying branched polyethyleneimine (PEI, 25 kDa) with biocompatible carboxylic acids either lactic acid or glycolic acid and incorporating choline-based ionic liquids (choline glycolate [CG] and choline lactate [CL]) to create advanced mPEI/ionic liquid (IL) formulations. These systems were designed to enhance DNA complexation, protect against enzymatic degradation, improve nanoparticle stability, and fine-tune physicochemical properties for optimal cellular interaction. The resulting polyplexes formed stable nanoparticles with diameters 100 -125 nm and surface charges of +24 to +29 mV, supporting efficient cellular uptake. Compared to unmodified PEI, the modified formulations showed markedly reduced cytotoxicity and significantly improved transfection performance. Among all tested combinations, the combination of lactic acid-modified PEI with choline glycolate (LA-mPEI + CG) was the most effective, achieving a 76% increase in transfection efficiency, a 66% improvement in cellular uptake, and 66% enhanced in cell viability. These findings highlight the synergistic advantage of combining carboxylic acid modification PEI with ionic liquid incorporation, providing a promising strategy for safer and more effective non-viral DNA delivery. This platform may serve as a foundation for future advancements in gene therapy and DNA vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.